Loewen, Ondaatje, McCutcheon Initiates Independent Analyst Coverage on Cynapsus Therapeutics
(firmenpresse) - TORONTO, ONTARIO -- (Marketwire) -- 02/29/12 -- Cynapsus Therapeutics Inc. (TSX VENTURE: CTH), a specialty pharmaceutical company developing a rescue therapy for Parkinson's disease, today announced that Loewen, Ondaatje, McCutcheon Limited ("LOM") has initiated analyst coverage of Cynapsus.
For further information and access to the report, please contact LOM at (416) 964-4455 or by email at . In a few days it is anticipated that the report will be posted to the Cynapsus web site, .
"We are pleased to have this independent research coverage by LOM, as it demonstrates that Cynapsus is of substantial interest to sophisticated institutional buyers," said Anthony Giovinazzo, President and CEO of Cynapsus.
The report, the opinions expressed by the analyst and the estimates are solely the work of the LOM analyst and Cynapsus neither approves nor disapproves of them.
About Loewen, Ondaatje, McCutcheon Limited (LOM)
LOM is a client-focused, research-driven, independent, international investment dealer. The firm is dedicated to helping its clients achieve their financial and strategic objectives through the effective integration of services provided by its five major disciplines: Research, Sales, Trading, Investment Banking and European Network. LOM is a member CIPF. LOM's strategy is to develop long-term relationships both with a select group of growth-orientated companies and with our institutional clients.
About Cynapsus Therapeutics
Cynapsus is a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease. Parkinson's disease is a chronic and progressive neurodegenerative disease that impacts motor activity, and its prevalence is increasing with the aging of the population. It is estimated that between 25 percent and 50 percent of patients experience "off episodes" in which they have impaired movement or speaking capabilities. Current medications only control the disease's symptoms, and most drugs become less effective over time as the disease progresses.
Cynapsus' lead drug candidate, APL-130277, is an easy-to-administer, fast-acting and oral reformulation of an approved drug, apomorphine, used to rescue patients from off episodes. Cynapsus is focused on rapidly maximizing the value of APL-130277 by completing pivotal studies in advance of a New Drug Application expected to be submitted in 2013 or 2014. Cynapsus anticipates out-licensing to an appropriate pharmaceutical partner before such an application is submitted.
More information about Cynapsus (TSX VENTURE: CTH) is available at and at the System for Electronic Document Analysis and Retrieval (SEDAR) at .
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of applicable Canadian securities legislation. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Cynapsus to be materially different from those expressed or implied by such forward-looking statements, including but not limited to those risks and uncertainties relating to Cynapsus' business disclosed under the heading "Risk Factors" in Cynapsus' current Annual Information Form and its other filings with the various Canadian securities regulators which are available online at . Although Cynapsus has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Cynapsus does not undertake to update any forward-looking statements, except in accordance with applicable securities laws.
The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.
Cynapsus Therapeutics Anthony Giovinazzo President and CEO (416) 703-2449 x225
Cynapsus Therapeutics Andrew Williams COO & CFO (416) 703-2449 x253
Media Contacts: Russo Partners LLC Ian Stone (619) 528-2220
Russo Partners LLC Robert E. Flamm, Ph.D. (212)-845-4226
TEMECULA, CA -- (Marketwired) -- 11/24/15 -- Dr. Richard Balikian, a with offices in Del Mar and Murrieta, CA, is now offering the "lunch hour Quad eyelift." After years of crafting his skills in , Dr. Balikian can now provide a Quad Eyelift, ...
GERMANTOWN, MD -- (Marketwired) -- 11/24/15 -- Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells ...
SANTA MONICA, CA -- (Marketwired) -- 11/23/15 -- , the first Practice Growth Platform for healthcare providers, announced today the closing of a $10M Series A round of funding. San Francisco-based Toba Capital, which invests primarily in business softwar ...
DORAL, FL -- (Marketwired) -- 11/23/15 -- In Ovations Holdings, Inc. (OTC PINK: INOH) is pleased to announce it has entered into a strategic marketing agreement with Al Lee and Associates, Inc. (ALA) to offer their state-of-the-art medical billing servic ...
BETHESDA, MD -- (Marketwired) -- 11/23/15 -- , a developer of topical pharmaceutical and consumer healthcare products for site-specific pain, therapeutic dermatologics and orphan disorders, today announced the dosing of the first patient in a randomized, ...